Showing results (111-120 of 125) with videos related to
Sort By:
Pageof 13
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 9, 2019
Hematopoietic Stem Cell Transplantation in Solid Organ Recipients with Emphasis on Transplant Complications: A Nationwide Retrospective Survey on Behalf of the Japan Society for Hematopoietic Stem Cell Transplantation Transplant Complications Working GroupAkihito Shinohara, Kumi Oshima, Shigeo Fuji, et al.Bone Marrow Transplantation|January 9, 2021
Stopping tyrosine kinase inhibitors started after allogeneic HCT in patients with Philadelphia chromosome-positive leukemiaHideki Nakasone, Shinichi Kako, Takehiko Mori, et al.Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|August 2, 2023
Clinical significance of late CMV disease in adult patients who underwent allogeneic stem cell transplantHiroaki Shimizu, Yuho Najima, Shinichi Kako, et al.International Journal of Hematology|May 20, 2025
Safety of hematopoietic stem cell donation from young related donors following the lowering of the age of legal adulthood in JapanTsuneaki Hirakawa, Hiromasa Yabe, Masayuki Hino, et al.Leukemia Research|August 23, 2024
Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocolsHiroaki Shimizu, Jun Kato, Susumu Tanoue, et al.Cancer Science|May 17, 2024
The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantationYutaka Shimazu, Junya Kanda, Kazuhito Suzuki, et al.Blood Cancer Discovery|September 2, 2025
Identification of a CD138-negative therapy-resistant subpopulation in multiple myeloma with vulnerability to splicing factor inhibitionTakahiro Kamiya, Masahiko Ajiro, Motohiko Oshima, et al.Haematologica|July 20, 2023
Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugsHiroyuki Takamatsu, Tomohiro Matsuda, Shohei Mizuno, et al.Cytotherapy|June 24, 2023
Adverse impact of delay of platelet recovery after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma and multiple myelomaYosuke Okada, Fumihiko Kimura, Naoki Kurita, et al.Transplantation and Cellular Therapy|June 25, 2021
Novel Indicators of Transplant Outcomes for PhALL: Current Molecular-Relapse-Free SurvivalHideki Nakasone, Shinichi Kako, Takayoshi Tachibana, et al.Pageof 13